← Back
Data updated: Mar 29, 2026
AbbVie
ABBV ImmunologyOncologyNeurology
Big Pharma
Immunology and oncology specialist spun from Abbott in 2013. Humira successor portfolio includes Skyrizi and Rinvoq. Expanded into aesthetics via Allergan acquisition.
$56.3B
Revenue (2024)
$310.0B
Market Cap
-
Trials
140
Approved (2yr)
Key Drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Competitive Matchups Pro
Loading...
Loading...
Recent Activity
VENCLEXTA 2026-02-19
Efficacy
TRETINOIN 2026-02-10
ACYCLOVIR 2026-01-22
Labeling
CYCLOSPORINE 2026-01-21
HUMIRA 2025-12-23
Labeling
NALBUPHINE HYDROCHLORIDE 2025-12-22
Labeling
NALBUPHINE HYDROCHLORIDE 2025-12-22
Labeling
NALBUPHINE HYDROCHLORIDE 2025-12-22
Labeling
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Immunology 26%
3 drugs Phase 3: 53 Phase 2: 28 Phase 1: 18
Oncology 24%
3 drugs Phase 3: 25 Phase 2: 36 Phase 1: 87
Neurology 20%
8 drugs Phase 3: 36 Phase 2: 13 Phase 1: 13
Infectious Disease 16%
7 drugs Phase 3: 31 Phase 2: 7 Phase 1: 6
Ophthalmology 13%
7 drugs Phase 3: 20 Phase 2: 7 Phase 1: 14
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
GSK big-pharma
Infectious Disease, Oncology, Immunology, Neurology
Roche big-pharma
Oncology, Neurology, Ophthalmology, Immunology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Infectious Disease, Neurology
Pfizer big-pharma
Oncology, Infectious Disease, Immunology
Novartis big-pharma
Oncology, Immunology, Ophthalmology
Active (67)
EMRELIS EMBLAVEO VYALEV RINVOQ LQ VUITY QULIPTA ORIAHNN (COPACKAGED) DURYSTA UBRELVY RINVOQ SKYRIZI ORILISSA MAVYRET VENCLEXTA VRAYLAR VIBERZI KYBELLA AVYCAZ DUOPA NAMZARIC DALVANCE FETZIMA OXYTROL FOR WOMEN LINZESS RECTIV VIIBRYD TEFLARO LASTACAFT ZYMAXID SAPHRIS ACUVAIL OZURDEX CREON SAVELLA LATISSE BYSTOLIC COMBIGAN ACULAR LS OXYTROL HUMIRA RESTASIS RESTASIS MULTIDOSE SYNTHROID ALPHAGAN P KALETRA DEPAKOTE ER GENGRAF CYCLOSPORINE CELEXA ZEMPLAR CRINONE ACYCLOVIR ULTANE OCUFLOX LUPRON DEPOT-PED KIT ACULAR BOTOX COSMETIC BOTOX SURVANTA LUPRON DEPOT FML FORTE BETAGAN DEPAKOTE CARAFATE INFED PRED FORTE PRED MILD
Discontinued (132)
TRETINOIN NALBUPHINE HYDROCHLORIDE LUPRON ALPHAGAN POLYTRIM TRICOR TRILIPIX ALORA SULFADIAZINE FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER LEXAPRO ESTRACE DELZICOL CANASA LUPANETA PACK BYVALSON URSO 250 URSO FORTE NORVIR ASACOL HD NIMBEX PRESERVATIVE FREE NIMBEX HYDROXYPROGESTERONE CAPROATE NIASPAN TITRATION STARTER PACK NIASPAN NORINYL 1+35 21-DAY NORINYL 1+35 28-DAY LUMIGAN ENABLEX FIORINAL FIORINAL W/CODEINE KADIAN RAPAFLO DEPACON DEPAKENE ANDRODERM VIEKIRA PAK (COPACKAGED) TECHNIVIE VIEKIRA XR NAMENDA XR BIAXIN XL BIAXIN TARKA NAMENDA MIVACRON MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER PRED-G K-TAB GELNIQUE BREVICON 28-DAY
+82 more
Company Info
- First Approval
- 1944-07-31
- Latest
- 2026-02-19
- Applications
- 224
FDA Sponsor Names
ALLERGANALLERGAN HERBERTABBVIE ENDOCRINE INCABBVIEABBVIE INC +1